白蛋白结合型紫杉醇的作用机制和其给药系统的研究进展被引量：7

下载PDF

导出

摘要紫杉烷类药物是被批准用于临床治疗肿瘤的重要新型药物,主要用于转移性乳腺癌、卵巢癌和非小细胞肺癌的治疗。然而,目前市售的溶剂型紫杉醇尽管采用适当的术前用药,仍然具有与溶剂相关的严重副作用和过敏反应。白蛋白结合型紫杉醇(nab-paclitaxel)是一种新型的无溶剂紫杉醇,它不需要合成的溶剂作为载体,不需要皮质类固醇或抗组胺药物等预处理,静脉滴注时间短(30min)。其利用了白蛋白的自然生物特性,通过gp-60(糖基化囊膜蛋白)介导的内皮细胞跨膜转运和一种与白蛋白结合的蛋白SPARC(一种酸性的富含半胱氨酸的分泌蛋白)的相互作用而增加肿瘤组织对紫杉醇的摄取和蓄积。临床前模型研究证实白蛋白结合型紫杉醇与溶剂型紫杉醇相比,抗肿瘤活性明显增强。以此为基础,近年国内外进行了一系列白蛋白结合型紫杉醇应用于各种恶性肿瘤化疗的临床研究,取得了令人鼓舞的效果。本文对白蛋白结合型紫杉醇的抗癌机制、体内运输机制和临床研究进行综述。

作者秦洁莉

机构地区包头医学院第二附属医院

出处《北方药学》 2014年第9期71-74,共4页 Journal of North Pharmacy

关键词 NAB-PACLITAXEL 作用机制转运机制癌症紫杉烷

分类号 R730.3 [医药卫生—肿瘤]

引文网络
相关文献

参考文献46

1M.C. Wani, H.L. Taylor, M.E. Wall, P. Coggon, A.T. MePhail, Plant antitumor agents.VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevi- folia, J. Am. Chem. Soc. 93( 1971)2325-2327.
2P.B. Schiff, J. Fant, S.B. Horwitz, Promotion of microtubule as- sembly in vitro by taxol, Nature 277(1979)665-667.
3P.B. Schiff, S.B. Horwitz, Taxol stabilizes microtubules in mouse fibroblast cells,Proc. Natl. Acad. Sci. U. S. A.77(1980) 1561-1565.
4A.J. ten Tile, J. Verweij, W.J. Loos, A. Sparreboom, Pharma- cological effects of formulation vehicles: implications for cancer chemotherapy, Clin. Pharmacokinet.42(2003)665-685.
5J.D. Adams, K.P. Flora, B.R. Goldspiel, J.W. Wilson, S.G. Arbuck, R. Finley, Taxol: a history of pharmaceutical develop- ment and current pharmaceutical concerns,J. Natl. Cancer Inst. Monogr. 15( 1993)141-147.
6Taxotere (doeetaxel) [Package Insert], 2010.
7W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, K.Y. Look, D.L.Clarke-Pearson, M. Davidson, Cy- clophosphamide and cisplatin compared with paclitaxel and cis- platin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med. 334( 1996)1-6.
8J.M. Nabhohz, K. Gelmon, M. Bontenbal, M. Spielmann, G. Catimel, P. Conte, U.Klaassen, M. Namer, J. Bonneterre, P. Fu- moleau, B. Winograd, Muhicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer, J. Clin. Oncol. 14(1996)1858-1867.
9E.P. Mamounas, J. Bryant, B. Lembersky, L. Fehrenbacher, S.M. Sedlacek, B. Fisher,D.L. Wickerham, G. Yothers, A. So- ran, N. Wolmark, Paclitaxel after doxorubicin plus cyclophos- phamide as adjuvant chemotherapy for node-positive breast can- cer: results from NSABP B-28, J. Clin. Oncol. 23 (2005)3686- 3696.
10P. Bonomi, K. Kim, D. Fairclough, D. Celia, J. Kugler, E. Rowinsky, M. Jiroutek, D.Johnson, Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with eisplatin versus etoposide with eisplatin: results of an Eastern Cooperative Oncology Group trial, J. Clin. Oncol. 18(2000)623-631.